IO Biotech, Inc.

IO Biotech, Inc. is a clinical-stage biopharmaceutical company specializing in immune-modulating cancer therapies. Their lead product candidate, IO102-IO103, targets immunosuppressive proteins such as IDO and PD-L1, and is in phase 2 clinical trial for melanoma and phase 1 trials for lung, head and neck, bladder, and melanoma cancer. Additionally, they are developing IO112, a product candidate designed to target T cells recognizing epitopes derived from Arginase 1 for cancer treatment.

Products

• IO102-IO103 (phase 2 clinical trial for melanoma, phase 1 trials for lung, head and neck, bladder, and melanoma cancer)

• IO112 (in development for cancer treatment)